OBJECTIVE: Longitudinal studies have begun to clarify the phenotypic characteristics of adolescents and young adults at clinical high risk for psychosis. This 8-site randomized trial examined whether a 6-month program of family psychoeducation was effective in reducing the severity of attenuated positive and negative psychotic symptoms and enhancing functioning among individuals at high risk. METHOD: Adolescents and young adults (mean age 17.4 ± 4.1 years) with attenuated positive psychotic symptoms, brief and intermittent psychosis, or genetic risk with functional deterioration were randomly assigned to 18 sessions of family-focused therapy for individuals at clinical high risk (FFT-CHR) in 6 months or 3 sessions of family psychoeducation (enhanced care [EC]). FFT-CHR included psychoeducation about early signs of psychosis, stress management, communication training, and problem-solving skills training, whereas EC focused on symptom prevention. Independent evaluators assessed participants at baseline and 6 months on positive and negative symptoms and social-role functioning. RESULTS: Of 129 participants, 102 (79.1%) were followed up at 6 months. Participants in FFT-CHR showed greater improvements in attenuated positive symptoms over 6 months than participants in EC (F1,97 = 5.49, p = .02). Negative symptoms improved independently of psychosocial treatments. Changes in psychosocial functioning depended on age: participants more than 19 years of age showed more role improvement in FFT-CHR, whereas participants between 16 and 19 years of age showed more role improvement in EC. The results were independent of concurrent pharmacotherapy. CONCLUSION: Interventions that focus on improving family relationships may have prophylactic efficacy in individuals at high risk for psychosis. Future studies should examine the specificity of effects of family intervention compared to individual therapy of the same duration and frequency. Clinical trial registration information-Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis; http://clinicaltrials.gov/; NCT01907282.
RCT Entities:
OBJECTIVE: Longitudinal studies have begun to clarify the phenotypic characteristics of adolescents and young adults at clinical high risk for psychosis. This 8-site randomized trial examined whether a 6-month program of family psychoeducation was effective in reducing the severity of attenuated positive and negative psychotic symptoms and enhancing functioning among individuals at high risk. METHOD: Adolescents and young adults (mean age 17.4 ± 4.1 years) with attenuated positive psychotic symptoms, brief and intermittent psychosis, or genetic risk with functional deterioration were randomly assigned to 18 sessions of family-focused therapy for individuals at clinical high risk (FFT-CHR) in 6 months or 3 sessions of family psychoeducation (enhanced care [EC]). FFT-CHR included psychoeducation about early signs of psychosis, stress management, communication training, and problem-solving skills training, whereas EC focused on symptom prevention. Independent evaluators assessed participants at baseline and 6 months on positive and negative symptoms and social-role functioning. RESULTS: Of 129 participants, 102 (79.1%) were followed up at 6 months. Participants in FFT-CHR showed greater improvements in attenuated positive symptoms over 6 months than participants in EC (F1,97 = 5.49, p = .02). Negative symptoms improved independently of psychosocial treatments. Changes in psychosocial functioning depended on age: participants more than 19 years of age showed more role improvement in FFT-CHR, whereas participants between 16 and 19 years of age showed more role improvement in EC. The results were independent of concurrent pharmacotherapy. CONCLUSION: Interventions that focus on improving family relationships may have prophylactic efficacy in individuals at high risk for psychosis. Future studies should examine the specificity of effects of family intervention compared to individual therapy of the same duration and frequency. Clinical trial registration information-Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis; http://clinicaltrials.gov/; NCT01907282.
Authors: K A Hawkins; T H McGlashan; D Quinlan; T J Miller; D O Perkins; R B Zipursky; J Addington; S W Woods Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: Alison R Yung; Lisa J Phillips; Barnaby Nelson; Shona M Francey; Hok PanYuen; Magenta B Simmons; Margaret L Ross; Daniel Kelly; Kathryn Baker; G Paul Amminger; Gregor Berger; Andrew D Thompson; Annette Thampi; Patrick D McGorry Journal: J Clin Psychiatry Date: 2010-10-19 Impact factor: 4.384
Authors: Sona Dimidjian; Steven D Hollon; Keith S Dobson; Karen B Schmaling; Robert J Kohlenberg; Michael E Addis; Robert Gallop; Joseph B McGlinchey; David K Markley; Jackie K Gollan; David C Atkins; David L Dunner; Neil S Jacobson Journal: J Consult Clin Psychol Date: 2006-08
Authors: G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger Journal: Arch Gen Psychiatry Date: 2010-02
Authors: David J Miklowitz; David A Axelson; Boris Birmaher; Elizabeth L George; Dawn O Taylor; Christopher D Schneck; Carol A Beresford; L Miriam Dickinson; W Edward Craighead; David A Brent Journal: Arch Gen Psychiatry Date: 2008-09
Authors: Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson Journal: Arch Gen Psychiatry Date: 2002-10
Authors: Mary P O'Brien; David J Miklowitz; Kristin A Candan; Catherine Marshall; Isabel Domingues; Barbara C Walsh; Jamie L Zinberg; Sandra D De Silva; Kristen A Woodberry; Tyrone D Cannon Journal: J Consult Clin Psychol Date: 2013-11-04
Authors: David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Amy S Garrett; Manpreet K Singh; Catherine A Sugar; Kiki D Chang Journal: Early Interv Psychiatry Date: 2017-08-04 Impact factor: 2.732
Authors: Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli Journal: World Psychiatry Date: 2018-06 Impact factor: 49.548
Authors: Jean Addington; Donald Addington; Sabina Abidi; Thomas Raedler; Gary Remington Journal: Can J Psychiatry Date: 2017-07-21 Impact factor: 4.356
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306